Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas

KRAS(G12C) inhibitors have revolutionized the clinical management of patients with KRAS(G12C)-mutant lung adenocarcinoma. However, patient exposure to these inhibitors leads to the rapid onset of resistance. In this study, we have used genetically engineered mice to compare the therapeutic efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Salmón, Marina, Álvarez-Díaz, Ruth, Fustero-Torre, Coral, Brehey, Oksana, Lechuga, Carmen G., Sanclemente, Manuel, Fernández-García, Fernando, López-García, Alejandra, Martín-Guijarro, María Carmen, Rodríguez-Perales, Sandra, Bousquet-Mur, Emily, Morales-Cacho, Lucía, Mulero, Francisca, Al-Shahrour, Fátima, Martínez, Lola, Domínguez, Orlando, Caleiras, Eduardo, Ortega, Sagrario, Guerra, Carmen, Musteanu, Monica, Drosten, Matthias, Barbacid, Mariano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065067/
https://www.ncbi.nlm.nih.gov/pubmed/36928090
http://dx.doi.org/10.1172/JCI164413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065067/
https://www.ncbi.nlm.nih.gov/pubmed/36928090
http://dx.doi.org/10.1172/JCI164413

Ejemplares similares